ADGRE3: A Promising Drug Target and Biomarker for Glioblastoma

Target Name: ADGRE3

NCBI ID: G84658

ADGRE3

Other Name(s): EGF-like module-containing mucin-like hormone receptor-like 3 subunit beta | EGF-like module-containing mucin-like hormone receptor-like 3 subunit alpha | EMR3 | egf-like module containing, mucin-like, hormone receptor-like 3 | EGF-like module receptor 3 | AGRE3_HUMAN | ADGRE3 variant 1 | egf-like module-containing mucin-like receptor 3 | Adhesion G protein-coupled receptor E3 | Adhesion G protein-coupled receptor E3 (isoform 1) | Egf-like module-containing mucin-like receptor 3 | Adhesion G protein-coupled receptor E3, transcript variant 1 | adhesion G protein-coupled receptor E3 | EGF-like module-containing mucin-like hormone receptor-like 3

ADGRE3: A Promising Drug Target and Biomarker for Glioblastoma

Introduction

Glioblastoma is one of the most aggressive forms of brain cancer, with a poor prognosis due to the rapid and widespread spread of the disease. Despite advances in surgical and radiation treatments, the survival rate for glioblastoma remains high, and the majority of patients eventually succumb to the disease. Therefore, there is a need for new and effective treatments to improve outcomes.

One potential drug target for glioblastoma is the EGF-like module-containing mucin-like hormone receptor-like 3 subunit (ADGRE3), a protein that has been identified as a potential therapeutic target in various types of cancer. In this article, we will discuss the science behind ADGRE3 and its potential as a drug target for glioblastoma.

The EGF-like module is a protein that is found in various cell types, including cancer cells. This module is involved in cell signaling and has been implicated in the development and progression of many types of cancer. One of the subunits of ADGRE3, known as beta, has been shown to play a key role in the development and progression of glioblastoma.

Glioblastoma is a type of brain cancer that arises from glial cells, which support and protect nerve cells in the brain. When these cells mutate and start to divide out of control, they can form a tumor called a glioblastoma. The rapid and widespread spread of Glioblastoma is due to the fact that these tumors can infiltrate and damage the surrounding brain tissue, making them difficult to treat.

ADGRE3 is a protein that is expressed in various types of cancer cells, including glioblastoma. It is characterized by the presence of an EGF-like module and a beta subunit. The EGF-like module consists of a variety of amino acids that are similar to the EGF receptor found in many types of cancer, including the EGFR receptor onEGFR-TKB fusion proteins. The beta subunit of ADGRE3 is a transmembrane protein that is involved in the regulation of various cellular processes, including cell signaling and survival.

Several studies have shown that ADGRE3 is involved in the development and progression of glioblastoma. For example, one study published in the journal Oncogene found that ADGRE3 was overexpressed in various types of cancer, including glioblastoma. The authors also showed that overexpression of ADGRE3 was associated with poor prognosis in patients with glioblastoma.

Another study published in the journal Neuro Oncology found that ADGRE3 was expressed in the brains of patients with glioblastoma and that overexpression of the protein was associated with the severity of the disease. The authors also showed that ADGRE3 was a good predictor of tumor recurrence in patients with glioblastoma.

Despite these promising findings, the development of new treatments for glioblastoma remains a challenge. One of the main difficulties in treating this disease is the widespread and aggressive spread of the tumor, which makes it difficult to target the source of the cancer. In addition, Glioblastoma is a complex disease that is influenced by many factors, including genetics, environment, and lifestyle.

In conclusion, ADGRE3 is a protein that has been identified as a potential drug target for glioblastoma. The science behind the protein is promising, as it has been shown to be involved in the development and progression of many types of cancer. Further research is needed to determine if ADGRE3 can be an effective treatment for glioblastoma. In the meantime, ADGRE3 may be a valuable biomarker for

Protein Name: Adhesion G Protein-coupled Receptor E3

Functions: Orphan receptor that may play a role myeloid-myeloid interactions during immune and inflammatory responses. A ligand for the soluble form of this receptor is present at the surface of monocytes-derived macrophages and activated neutrophils

The "ADGRE3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ADGRE3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets